Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mirexus Biotechnologies, Inc.

Request full access

Corn-based phytoglycogen nanoparticles for cosmetic and personal care

Kitchener, CanadaFounded 2008Biotech & Life Sciences

About Mirexus Biotechnologies, Inc.

Mirexus Biotechnologies Inc. was a Canadian biomaterials company specializing in the commercialization of PhytoSpherix™, a natural nanomaterial derived from non-GMO sweet corn. Founded in 2008 by four scientists from the University of Guelph—Professor John Dutcher, Dr. Anton Korenevski, Dr. Oleg Stukalov, and Dr. Erzebet Papp-Szabo—the company was built upon the discovery of naturally occurring, uniform polysaccharide nanoparticles in corn kernels. This discovery led to a patented, water-based extraction process to harvest the phytoglycogen.

The company's core business revolved around producing and selling PhytoSpherix™ and related branded products (EnerZea™, Adveen™, Susttain™) as a multi-functional active ingredient for the personal care and cosmetics industries. This plant-based glycogen serves as an anti-aging agent, moisturizer, and stabilizer in formulations. Its benefits include boosting collagen and hyaluronic acid production, reducing wrinkles, improving skin hydration, and enhancing the stability of other active ingredients. The business model focused on supplying this high-value ingredient to formulators of premium skincare products, positioning it as a safe, biodegradable, and non-toxic alternative to synthetic ingredients. Mirexus targeted markets in Europe and beyond, where demand for natural and sustainable ingredients is high.

In October 2022, Mirexus completed the sale of substantially all of its assets, with its core intellectual property and personal care applications being acquired by Mibelle Biochemistry, a Swiss ingredient manufacturer. The deal included an agreement for Mirexus to continue producing PhytoSpherix™ at its Guelph, Ontario facility under contract while Mibelle transitions production to Europe. This acquisition marked a strategic exit for Mirexus, which had raised over $16 million in funding from investors including GreenSky Capital, Goddard Enterprises Ltd., and Asahi Kasei Corporate Venture Capital.

Source: Dealroom company data

Mirexus Biotechnologies, Inc. in the Kitchener ecosystem

Live from Dealroom

The Mirexus Biotechnologies, Inc. office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Innovation, Science and Economic Development Canada
  • Department of Canadian Heritage

Series A3 investors entered at this stage

  • GreenSky Ventures
  • Goddard Enterprises
  • Asahi Kasei Ventures
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇦 Canada · Kitchener HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mirexus Biotechnologies, Inc. on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mirexus Biotechnologies, Inc. on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.